Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Docetaxel (DB01248)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01557959Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT00362882Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung CancerTreatment
NCT00118183Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerTreatment